STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed...
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio...
Morning Markets March S&P 500 futures this morning are up +1.29%. U.S. stock index futures are moderately higher this morning on reduced Russia-Ukraine tensions after Russia announced the start of a pullback...
Markets opened lower on Monday morning, but nothing held these two companies back.
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair...
Morning Markets March S&P 500 futures this morning are down -0.07%. U.S. stock index futures initially fell sharply in overnight trade, with March E-mini S&P futures dropping to a 2-week low on inflation...
Transaction is valued at $5.60 per share representing a total equity value of $604 million Represents a 54% premium to BDSI stock’s closing price of $3.64...
Shares of the small pharmaceutical company, which focuses on pain management, have been rising since it released updated guidance late last week.
RALEIGH, N.C., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company...
Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million...